MASLD/MASH Learning Center
Semaglutide for metabolic dysfunction-associated steatohepatitis (MASH): Estimating eligibility from the 2021-2023 National Health and Nutrition Examination Survey (NHANES)
December 2025
No abstract
Read More
From mechanisms to management: Early detection and improved treatment of MASLD and its related hepatocellular carcinoma
December 2025
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease and is estimated to affect over a billion people worldwide. MASLD patients may progress to more severe forms, including metabolic dysfunction-associated steatohepatitis (MASH) and hepatocellular carcinoma (HCC) with or without cirrhosis. Recent data demonstrated that HCC represents the fifth most common cancer and is the second leading cause of cancer-related death globally, and MASLD has...
Read More
Polymer-lipid hybrid nanoparticles incorporating green coffee extract: enhancing treatment for hepatic steatosis and fibrosis through metabolomic insights
December 2025
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 30% of adults globally. Its severe form, metabolic dysfunction-associated steatohepatitis (MASH), results in liver damage due to a combination of steatosis and fibrosis. Green coffee extract (GCE) derived from unroasted coffee beans demonstrates therapeutic potential for MASLD/MASH attributed to its rich profile of bioactive compounds. However, challenges remain regarding bioavailability and understanding of...
Read More
Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review
December 2025
Glucagon-like peptide-1 (GLP-1), an incretin hormone, plays a crucial role in glucose homeostasis by stimulating insulin secretion, suppressing glucagon release, and delaying gastric emptying. Its therapeutic potential was long realized, leading to the development of the first GLP-1 receptor agonist, exenatide, followed by liraglutide, dulaglutide, semaglutide, and tirzepatide. Semaglutide is available as a weekly subcutaneous injection with high bioavailability. Semaglutide is the only GLP-1...
Read More
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
November 2025
Globally, metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease, affecting up to one in three people in the general population, with an estimated increase in prevalence of more than 50% in the last three decades. The rise in prevalence of MASLD will result in substantial increases in the number patients with decompensated cirrhosis and those developing liver cancer by 2030. Despite the complex pathobiology of MASLD, two major breakthroughs...
Read More
Aspirin Use and Mediterranean Diet Adherence as Factors Associated With Overall Mortality in Patients With MASLD in NHANES
November 2025
CONCLUSIONS: Aspirin use is independently associated with a several-fold increased mortality risk in older MASLD patients without prior CVD, an effect partly mitigated by high adherence to the Mediterranean diet. Aspirin for primary CVD prevention should be used with caution in this population. Aspirin use and diet are important, often uncontrolled factors associated with mortality in MASLD clinical trials.
Read More
Metabolic Dysfunction-Associated Steatohepatitis in Focus: Pathogenesis, Non-Invasive Diagnostics, and Future Approaches
November 2025
Metabolic dysfunction-associated steatohepatitis (MASH) has become a critical public health concern, representing the progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD). MASH is characterized by hepatic steatosis, inflammation, hepatocyte ballooning, and fibrosis, which increase the risk of cirrhosis and hepatocellular carcinoma. Closely linked to obesity, insulin resistance, and metabolic syndrome, MASH affects a significant proportion of the global population,...
Read More
Evaluation of a novel albumin platelet product (APP) fibrosis index and three non-invasive fibrosis indices in metabolic dysfunction-associated steatotic liver disease
November 2025
CONCLUSION: APP outperformed FIB4 in detecting cirrhosis or advanced fibrosis among patients with DM and was comparable in non-DM patients. Revised FIB-4 thresholds may be needed in MASLD/MASH patients with DM to improve its diagnostic accuracy.
Read More
Ginsenoside Rg2 ameliorates metabolic dysfunction-related steatohepatitis via the Nrf2 pathway by suppressing inflammation, apoptosis, oxidative stress and fibrosis
November 2025
CONCLUSION: This study is the first to confirm that G-Rg2 binds to and regulates Nrf2, and further illustrates that it alleviates MASH by activating the NRF2 signaling pathway to inhibit inflammation, cell apoptosis, oxidative stress, and fibrosis. This establishes a conceptual foundation for the future use of G-Rg2 in MASH treatment and supports the development of natural product-based therapeutic strategies derived from dietary sources.
Read More
Inhibiting peripheral serotonin activates liver AMPK and reduces monocyte-derived macrophages and fibrosis
November 2025
Monocyte-derived liver macrophages are critical in the pathogenesis of metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, but their recruitment mechanisms remain unclear. Serotonin (5-hydroxytryptamine [5HT]) is a conserved monoamine synthesized by tryptophan hydroxylase 1 (Tph1) in peripheral tissues and Tph2 in the brain. We show that, in mice housed at thermoneutrality and fed a high-fat, high-fructose diet, inhibition of peripheral serotonin (pe5HT) through genetic...
Read More
Tetrahedral Framework Nucleic Acid-Based Delivery of miR-34a Inhibitor for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
November 2025
Metabolic dysfunction-associated steatohepatitis (MASH), a metabolic liver disorder with severe complications, features hepatic inflammation and oxidative stress. MiR-34a dysregulation is a critical contributor to MASH progression, making it a promising therapeutic target. However, clinical translation of miR-34a-targeted interventions remains limited by poor stability and cellular uptake. Here, we developed a miRNA-binding tetrahedral framework nucleic acids (TDN)-based system, termed Tm to...
Read More
Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction-Associated Steatohepatitis
November 2025
CONCLUSIONS: LYS006 20 mg bid monotherapy and LYS006 20 mg bid+tropifexor 200 μg qd therapy were well tolerated with the exception of a high frequency of pruritus in the combination arm, consistent with the now known pharmacologic effect of farnesoid X receptor agonists. The greater reductions in ALT and liver fat in the combination arm versus monotherapy arm were similar to those observed with tropifexor as monotherapy in a previously reported phase 2 clinical trial, and clear additional...
Read More